gel-e wins USD1.4m hemostatic development order from the US Military.
M2 EQUITYBITES-February 20, 2018-gel-e wins USD1.4m hemostatic development order from the US Military
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Medical device company gel-e Inc reported on Monday the receipt of USD1.4m in grant from the Department of Defense (DoD) through the US Army Medical Research and Material Command (USAMRMC) to develop advanced solutions for prolonged field care.
The company added that the military grant will support the development of an expanding foam hemostat for the treatment of internal non-compressible haemorrhage that typically results from being struck by shrapnel or a significant concussive force.
Under the company's hemostatic platform, it has been optimising flowable formulations for internal and surgical use. Consequently, certain product candidates have been identified that can be administered in far-forward locations to quickly stabilise internal injuries, allowing time for evacuation of the wounded to a field surgical OR.
In addition, the company has received an expansion of its SBIR Phase II grant to support additional seminal research into the development of new flowable, internal-use hemostatic formulations. The National Science Foundation order is based on previous success as a Phase I and II recipient.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Feb 20, 2018|
|Previous Article:||Steward announces agreement to become Malta's public health care partner and medical facility operator.|
|Next Article:||Affecto reports on Court of Arbitration's confirmation of CGI Nordic investments' redemption right; Trading in Affecto's shares suspended.|